CS Diagnostics disavows financial statements for 2022–2025 due to improper $499.4M intangible asset
CS Diagnostics Corp. announced on June 23, 2026 that its Board determined the company's previously issued financial statements for fiscal years ended December 31, 2022, 2023, 2024, and 2025 should no longer be relied upon. The primary issue is an approximately $499.4 million intangible asset recorded in connection with a September 4, 2023 transaction that management concluded was improperly recognized under a fair-value acquisition model rather than ASC 805-50 (common control transactions). The company has engaged Shah Teelani & Associates as its new independent auditor and KBF Advisory LLC as technical accounting advisor to conduct re-audits and restatements, which are expected to materially reduce reported total assets and stockholders' equity. Additionally, the company determined that audit reports issued by Olayinka Oyebola & Co. for historical periods should no longer be relied upon due to SEC regulatory restrictions on that firm.
Key facts
- Approximately $499.4 million intangible asset improperly recognized in September 4, 2023 transaction
- Affected Financial Statements: fiscal years ended December 31, 2022, 2023, 2024, and 2025
- Shah Teelani & Associates LLC engaged as current independent registered public accounting firm
- KBF Advisory LLC retained as technical accounting advisor
- Audit reports by Olayinka Oyebola & Co. determined unreliabl due to SEC restrictions on that firm
- Restatement expected to materially reduce total assets and stockholders' equity
- Management to evaluate ASC 805-50, ASC 730, ASC 350, ASC 820 accounting guidance
- Company anticipates filing restated financial statements for affected periods with 10-K for fiscal year ended December 31, 2025
Why it matters
The restatement addresses a fundamental breakdown in accounting controls over a material intangible asset recognized in 2023, directly impacting the company's reported balance sheet and equity, and the audit-firm issues signal previous governance gaps that required remediation before public investors can rely on the company's financial reports again.
Developing story
- NT 10-Q
- NT 10-K
- 8-Kthis filing
Share
Derived from 8-K filed 2026-06-23. Not investment advice. View the source filing on SEC.gov →